Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro

BACKGROUND: Identification of the antitumor role of tyrosine kinase inhibitors, such as TKI-258, may lead to novel therapeutics for Oral Squamous Cell Carcinoma (OSCC), which has high mortality rates. TKI-258 blocks Fibroblast Growth Factor Receptors (FGFRs), Platelet-Derived Growth Factor Receptors (PDGFRs), and Endothelial Growth Factor Receptor (VEGFRs). OBJECTIVE: This study aimed to evaluate the effect of TKI-258 treatment on cell proliferation in SCC-4 cells of OSCC. METHODS: BrdU and KI-67 assays were performed by using SCC-4 cells. Control was compare to 1, 5 and 10muM TKI-258 treatment. Control vehicle was compared to: 60muM LY294002 (LY), 2muM Wortmannin (WTN) and LY+WNT. Moreover, TKI 5muM treatment was compared to: TKI 5muM+LY; TKI 5 muM+WTN; TKI 5muM+LY+WTN. After 6h of treatments, immunofluorescence stained BrdU and KI-67 positive cells. Morphometry of proliferative cells was analyzed considering significance of p<0.05. RESULTS: BrdU and KI-67 assays results were similar for all experiments. TKI-258 treatment leads to an important reduction in proliferation rate in SCC-4 cells by in a concentration dependent manner. As expected, there was a significant reduction in the percentage of proliferative cells that had PI3K inhibited. When compared to TKI 5 treatment, proliferating cells were significantly lower with simultaneous PI3K inhibition. CONCLUSION: This study demonstrated that TKI-258 play an anti-proliferative role on SCC-4 cells of OSCC. It could be interesting to block multiples pathways such as FGFRs, PDGFRs and VEGFRs. Therefore, TKI-258 is a promising option for novel therapeutics for OSCC, especially if associated with PI3K inhibition.